INBX

Inhibrx Biosciences, Inc.

16.48 USD
-0.04 (-0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Inhibrx Biosciences, Inc. stock is down -51.73% since 30 days ago. The next earnings date is Jun 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 June’s closed higher than May. In the last 3 Unusual Options Trades, there were 1 PUT, 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 May 19:18 17 May, 2024 40.00 PUT 750 2
29 May 14:44 17 Jan, 2025 35.00 CALL 471 1551
29 May 17:47 20 Dec, 2024 30.00 CALL 100 37

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.